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ABSTRACT
Background: Balloon aortic valvuloplasty (BAV) is used as a 
palliative strategy in patients who are not eligible for valve 
replacement surgery, transcatheter aortic valve implantation, 
or as a bridge to these treatment modalities. The impact of 
BAV as a salvage procedure for patients in extreme clinical 
conditions (in extremis) is unknown. Methods: Patients with 
severe degenerative aortic stenosis undergoing BAV between 
July 2008 and January 2013 were evaluated. Patients were 
divided into the in-extremis group (defined by the presence of 
two or more of the following organ dysfunctions: mechanical 
ventilation, hemodynamic instability, dialysis, coagulopathy 
or severe hepatic dysfunction) and the control group, which 
included the remaining patients. Results: A total of 19 patients 
underwent BAV. The clinical condition in-extremis was present 
in 42.1% of them. Patients from the in-extremis group had a 
higher EUROSCORE II (41.1 ± 24.7 vs. 15.9 ± 14.0; P = 0.001) 
and LV ejection fraction lower than the control group (33.9 
± 17.3% vs. 49.0 ± 12.5; P = 0.04). None of the patients in 
the in-extremis group survived past the hospitalization period, 
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RESUMO
Valvuloplastia Aórtica por Cateter Balão na Estenose 
Aórtica Degenerativa: Impacto Terapêutico em 
Pacientes em Condição Clínica In Extremis
Introdução: A valvuloplastia aórtica por cateter balão (VAB) 
é utilizada como estratégia paliativa em pacientes inelegíveis 
tanto para troca valvar cirúrgica quanto para implante valvar 
aórtico transcateter, ou como ponte para essas modalidades 
de tratamento. Não se sabe o impacto terapêutico da VAB 
quando realizada como medida de salvamento para pacientes 
em condições clínicas extremas (in extremis). Métodos: Foram 
analisados pacientes com estenose aórtica grave de etiologia 
degenerativa submetidos à VAB entre julho de 2008 e janeiro 
de 2013. Os pacientes foram divididos entre o grupo in ex-
tremis (definido pela presença de duas ou mais das seguintes 
disfunções orgânicas: ventilação mecânica, instabilidade he-
modinâmica, terapia renal dialítica, coagulopatia ou disfunção 
hepática graves) e o grupo controle, que incluiu os demais 
pacientes. Resultados: Um total de 19 pacientes realizaram 
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whereas the control group mortality was 27.3% (P < 0.01). 
Conclusions: BAV has an unfavorable result in patients with 
severe degenerative aortic stenosis with two or more organ 
dysfunctions, that is, patients in extremis.
 
 
 
 
 
 
 
 
DESCRIPTORS: Aortic valve stenosis. Balloon valvuloplasty. 
Heart valve prosthesis implantation.
extremis), in an attempt to avoid death, at the expense 
of an improvement in the cardiac output compromised 
by the aortic valve stenosis.
The aim of this study was to evaluate the thera-
peutic impact of BAV in the treatment of degenerative 
aortic stenosis in patients with and without the clinical 
condition in extremis.
METHODS
This is a retrospective study, conducted in a single 
quaternary care service of high complexity cardiology. 
The research was based on a database analysis and 
review of the electronic clinical record.
Study population
Between July 2008 and January 2013, all patients 
undergoing BAV for treatment of degenerative aortic 
stenosis at Instituto do Coração, Hospital das Clínicas 
da Faculdade de Medicina, Universidade de São Paulo 
(Incor-HCFMUSP), in São Paulo (SP) were reviewed. 
This study did not include procedures for treatment of 
congenital aortic stenosis.
Procedure
All procedures were performed by retrograde route, 
by puncturing the common femoral artery (right or left), 
and by the application of a long sheath with diameter 
10F. Unfractionated heparin was administered to all 
patients. The size of the balloon catheter used in each 
procedure was chosen at the discretion of the surgeon. 
In some cases, the balloon inflation was preceded by 
a rapid stimulation (fast pacing), with a temporary 
pacemaker placed in the right ventricle.
The measurement of the aortic transvalvular gra-
dient was performed before and after the BAV, through 
intracavitary manometry and transthoracic echocardio-
graphy. The sheath was removed immediately after the 
VAB no período. A condição clínica in extremis esteve pre-
sente em 42,1%. Os pacientes do grupo in extremis tiveram 
EUROSCORE II mais elevado (41,1 ± 24,7 vs. 15,9 ± 14,0; 
P = 0,01) e fração de ejeção do VE mais baixa que o grupo 
controle (33,9 ± 17,3% vs. 49,0 ± 12,5%; P = 0,04). Nenhum 
paciente do grupo in extremis sobreviveu ao período intra-
hospitalar, enquanto que, no grupo controle, a mortalidade 
foi de 27,3% (P < 0,01). Conclusões: Para o tratamento de 
pacientes com estenose aórtica grave de etiologia degenera-
tiva, a VAB tem resultado desfavorável quando indicada para 
pacientes com duas ou mais disfunções orgânicas, ou seja, 
em condição clínica in extremis.
DESCRITORES: Estenose da valva aórtica. Valvuloplastia com 
balão. Implante de prótese de valva cardíaca.
D egenerative aortic stenosis is the valvulopathy whose incidence most increases with aging. Its prevalence in individuals over 75 years of age 
is estimated at 4.6%.1 The prognosis after the onset 
of symptoms is poor, with survival time between one 
and three years.2
The treatment of choice for symptomatic patients 
with severe aortic stenosis secondary to valve degen-
eration is aortic valve replacement surgery (AoVR).3 
However, approximately 30% of these patients do not 
receive surgical treatment due to the high periopera-
tive risk arising from multiple comorbidities.4 Thus, less 
invasive modalities have emerged for the treatment of 
this valvulopathy, among which stand out the trans-
catheter aortic valve implantation (TAVI) and balloon 
aortic valvuloplasty (BAV).
TAVI was safe and effective in patients with high 
surgical risk, providing a reduction in mortality in 
patients whose surgical procedure was refused by the 
surgeon because of an excess of clinical comorbidities.5 
However, the anatomical prerequisites required, the high 
cost related to the procedure, and the low number of 
trained professionals capable of its performance make 
this option unavailable for most patients.
BAV is a procedure used as a palliative strategy in 
patients unfit for both surgical valve replacement and 
TAVI, or as a bridge to these treatment modalities.2,6-8 
Its low cost and wide availability in most cardiology 
centers justify its use for patients with prohibitive surgi-
cal risk, despite the high recurrence rate of symptoms 
and its ineffectiveness in reducing mortality.9,10
The best time to perform the BAV, in the context of 
symptomatic aortic stenosis, has not yet been defined. 
In most cases, the procedure is performed with urgency 
in patients refractory to optimized clinical treatment. 
In other times, however, BAV is performed as a meas- 
ure to rescue patients who already present multiple 
organ dysfunctions, i.e., extreme clinical conditions (in 
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procedure, with subsequent manual compression for 
hemostasis.
Procedural success was defined as the successful 
dilation of the aortic valve with the balloon catheter, 
in the absence of complications during the procedure.
Data collection
Clinical, echocardiographic, and hemodynamic data, 
and in-hospital outcomes were obtained retrospectively 
from the electronic case notes of each patient treated at 
Incor-HCFMUSP. After hospital discharge, the evaluation 
of cardiovascular events was performed by analyzing the 
electronic records, with supplementation by telephone 
contact, when needed.
The patients’ profile of disease severity was esti-
mated by EuroSCORE II and STS Risk Score. Severe 
pulmonary hypertension was defined as a systolic 
pressure in pulmonary artery (SPPA) ≥ 60 mmHg by 
echocardiography. Renal failure was characterized as 
the presence of creatinine clearance ≤ 60 mL/min.
The patients were divided in two groups: in extremis 
(defined by the presence of two or more of the follow-
ing dysfunctions: mechanical ventilation, hemodynamic 
instability, renal dialysis therapy, coagulopathy, or se-
vere liver dysfunction) and control, which included the 
remaining patients.
Statistical analysis
The analysis of clinical, echocardiographic, and 
hemodynamic data was performed using the software 
SPSS (IBM Corp., New York, USA). Continuous variables 
were described as mean and standard deviation and 
compared by Student’s t-test. Categorical variables were 
described as frequency, and percentage, and compared by 
the chi-squared or Fisher’s exact test, when appropriate. 
The survival analysis was performed by Kaplan-Meier 
method. A significance level of P < 0.05 was adopted.
RESULTS
A total of 19 patients with severe aortic stenosis 
with degenerative etiology were treated with BAV in the 
analyzed period. The study population was composed 
almost entirely by elderly people, and the mean age was 
77.7 ± 11.1 years. The predominant symptom before the 
procedure was dyspnoea, and all patients were classi-
fied as heart failure functional class III or IV. Among 
the comorbidities, severe pulmonary hypertension was 
particularly prominent, with 31.6% of patients, and 
renal failure was present in 73.7%. The mean of STS 
Risk Score was 36.6 ± 17.4 and that of EuroSCORE II 
was 26.5 ± 22.6. Other clinical characteristics of the 
patients are shown in Table 1.
Procedural success was achieved in 100% of the 
cases. The temporary pacemaker was used to promote 
rapid stimulation (fast pacing) in 68.4% of patients 
(Table 2). Significant reduction of the aortic transvalvular 
gradient was noted, both by echocardiography and by 
pressure measurements during the procedure (Figure 1).
The clinical condition in extremis was present in 
42.1% of patients (Table 3). When compared to the 
control group, patients in the in extremis group were 
younger (70.1 ± 10.0 vs. 83.3 ± 8.5 years; P <  0.01) 
TABLE 1 
Clinical characteristics
Variable n = 19
Age, years 77.7 ± 11.1
Female, n (%) 13 (68.4)
Arterial hypertension, n (%) 9 (47.4)
Diabetes, n (%) 5 (26.3)
Dyslipidemia, n (%) 7 (36.8)
Chronic obstructive pulmonary 
disease, n (%) 
4 (21.1)
Severe pulmonary hypertension, n (%) 6 (31.6)
Renal failure, n (%) 14 (73.7)
Previous acute myocardial infarct, n (%) 4 (21.1)
Previous CABG surgery, n (%) 4 (21.1)
Previous coronary angioplasty, n (%) 3 (15.8)
Previous stroke, n (%) 1 (5.3)
Clinical picture, n (%) 
Heart failure functional class III or IV 19 (100)
Angina 5 (26.3)
Current medication, n (%) 
Diuretic 17 (89.5)
Digitalis 5 (26.3)
Vasoactive drugs 8 (42.1)
Risk scores 
STS Risk Score 36.6 ± 17.4
EuroSCORE II 26.5 ± 22.6
Follow-up after discharge, days 268.3 ± 202.3
CABG = coronary artery bypass graft. 
TABLE 2 
Procedure characteristics
Variable n = 19
Success, n (%) 19 (100)
Use of pacemaker for rapid stimulation, n (%) 13 (68,4)
Vascular complications, n (%) 0
Stroke, n (%) 0
Death during the procedure, n (%) 0
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and had higher EuroSCORE II (41.1. ± 24.7 vs. 15.9 
± 14.0l; P <  0.01). In addition, the in extremis group 
had a lower left ventricle ejection fraction before the 
procedure versus the control group (33.9 ± 17.3% vs. 
49.0 ± 12.5%; P = 0.04). Hemodynamic and echocar-
diographic characteristics are shown in Table 4.
In both groups, there were no deaths during the 
procedure. None of the eight patients in the in extre-
mis group survived the in-hospital period, while in 
the control group the in-hospital mortality was 27.3% 
(P <  0.01). Survival at 180 days is shown in Figure 2.
Three patients (15.8%) of the control group were 
submitted to BAV as a bridge to other definitive treat-
ment: one patient underwent TAVI by transapical ap-
proach and died during the procedure, and two patients 
underwent AoVR (one of them was discharged and the 
other died in the immediate postoperative period). All 
patients who were discharged (42.1%) showed improve-
ment in their heart failure functional class. The mean 
follow-up was 268.3 ± 202.3 days.
DISCUSSION
This study was relevant in the analysis of the clini-
cal, echocardiographic, and hemodynamic characteris-
tics, as well as in the evolution of patients with severe 
degenerative aortic stenosis treated by BAV.
The high in-hospital mortality in the study reflects 
the clinical profile of extreme severity of the patients, 
mainly due to the presence of multiple comorbidities. 
There are no other studies in the literature that include 
a group of patients as severe as those described in 
this work. The mean STS Risk Score in the PARTNER 
study,5 which included only patients at high surgical 
risk or considered inoperable, was 11.6 ± 6.0, i.e., 
much lower than that of the present study (36.6 ± 17, 
4). Other studies involving only patients undergoing 
BAV also included patients with less severe conditions 
compared to the present study, with lower incidence of 
comorbidities and with lower risk scores.6,7,11-14
Most patients (73.7%) showed renal failure at the 
time of the procedure, and most had pulmonary artery 
pressure > 60 mmHg. Both conditions have been as-
sociated to an increase in mortality in earlier studys.9,15
In a study of 509 patients, Ben-Dor et al. de m- 
onstrated that the mortality after 5 months for patients 
with SPPA  > 60 mmHg was 49.1%, regardless of the 
type of treatment received (BAV, TAVI, or AoVR).16
Several studies have correlated the presence of 
renal insufficiency before the procedure with increased 
mortality.9,17,18 A study of 262 patients at high surgical 
risk undergoing BAV showed that creatinine clearance 
≤ 60 mL/min before the procedure is a strong predic-
tor of mortality.7
The absence of vascular complications in this study 
may be related to the use of sheaths with small calibre 
(10F) in all patients, as well as to the immediate with-
drawal of the sheath. Despite being related to a shorter 
hospital stay and a lower rate of blood transfusions in 
Figure 1 – LV-Ao gradient before and after balloon aortic valvuloplasty. 
LV, left ventricle, Ao, aorta; BAV, balloon aortic valvuloplasty.
TABLE 3 
Clinical characteristics by group
Variable 
In extremis
(n = 8)
Control
(n = 11) P
Age, years 70.1 ± 10.0 83.3 ± 
8.5
< 0.01
Female, n (%) 6 (75.0) 7 (63.6) 0.60
Systemic arterial 
hypertension, n (%) 
3 (37.5) 6 (54.5) 0.46
Diabetes, n (%) 3 (37.5) 2 (18.2) 0.35
Dyslipidemia, n (%) 2 (25.0) 5 (45.5) 0.36
Chronic obstructive 
pulmonary disease, n (%) 
3 (37.5) 1 (9.1) 0.13
Severe pulmonary 
hypertension, n (%) 
3 (37.5) 3 (27.3) 0.64
Renal failure, n (%) 7 (87.5) 7 (63.6) 0.24
Acute myocardial 
infarction, n (%) 
1 (12.5) 3 (27.3) 0.44
Previous CABG, n (%) 1 (12.5) 3 (27.3) 0.44
Previous coronary 
angioplasty, n (%) 
0 (0) 3 (27.3) 0.11
Previous stroke, n (%) 0 (0) 1 (9.1) 0.38
Vasoactive drugs use 6 (75.0) 2 (18.2) 0.01
Risk scores 
STS Risk Score 45.1 ± 15.9 30.4 ± 
16.3
0.07
EuroSCORE II 41.1 ± 24.7 15.9 ± 
14.0
0.01
CABG = coronary artery bypass graft.
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these cases, mortality was 50%. Recently, some studies 
have addressed the use of BAV as a bridge to TAVI, 
showing excellent results in the short and long term, 
when compared to BAV alone.6-8
The classification of patients according to the 
number of organ dysfunctions presented was of great 
importance to the understanding that there is a subgroup 
of more severe patients who evolve unfavourably, even 
after BAV. Patients with two or more organ dysfunc-
tions had significantly higher mortality when compared 
to patients in the control group. The main reason for 
the treatment of patients in the group in extremis 
with BAV was the presence of a clinical condition of 
extreme gravity, whether or not with cardiac etiology, 
in the presence of severe aortic stenosis. It was hoped 
that, in these patients, the reduction of the gradient 
in the left ventricular (LV) outflow would provide an 
improvement of their LV function to the point that 
they could recover from the critical hemodynamic 
state present during their admission. However, even 
with the decrease of the aortic transvalvular gradient 
and the increase in LV ejection fraction after the pro-
cedure, these results were not translated into clinical 
improvement, suggesting that these patients underwent 
the intervention too late.
Limitations of the study
The study had some limitations, such as the 
small number of patients included in the retrospective 
analysis of data and the fact that it was conducted in 
a single center.
TABLE 4 
Hemodynamic and echocardiographic characteristics
Variable
In extremis
(n = 8)
Control
(n = 11) P
Before valvuloplasty 
LV-Ao gradient (manometry), mmHg 70.6 ± 25.1 76.8 ± 23.1 0.59
LV-Ao gradient, peak (echocardiogram) mmHg 96.9 ± 35.6 85.9 ± 23.4 0.43
LV-Ao gradient, medium (echocardiogram) mmHg 55.9 ± 22.1 51.3 ± 15.8 0.60
Ejection fraction,% 33.9 ± 17.3 49.0 ± 12.5 0.04
Moderate or severe aortic regurgitation, n (%) 1 (12.5) 2 (18.2) 0.54
After valvuloplasty 
LV-Ao gradient (manometry), mmHg 41.3 ± 21.5 38.0 ± 24.9 0.77
LV-Ao gradient, peak (echocardiogram) mmHg 66.8 ± 19.2 57.5 ± 20.5 0.34
LV-Ao gradient, medium (echocardiogram) mmHg 31.8 ± 18.9 35.3 ± 12.3 0.63
Ejection fraction,% 39.1 ± 15.9 52.7 ± 13.8 0.06
Moderate or severe aortic regurgitation, n (%) 2 (25.0) 3 (27.3) 0.36
LV = left ventricle; Ao = aorta.
Figure 2 – Survival after aortic balloon valvuloplasty.
patients undergoing AoBV,19 vascular occlusion devices 
were not used in this study.
The division of patients according to the presence 
or absence of the clinical condition in extremis was 
extremely important for the understanding of the most 
appropriate time for performing BAV. The guidelines 
do not address BAV as a salvage therapy in patients 
in critical clinical condition with multiple organ dys-
function, but do suggest that its performance can be 
beneficial as a bridge to AoVR.2 In this study, only two 
patients underwent BAV as a bridge to AoVR, and in 
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CONCLUSIONS
Balloon aortic valvuloplasty for treatment of severe 
aortic stenosis with degenerative etiology has unfavor- 
able outcome when indicated for patients with two or 
more organ dysfunctions, i.e., in a clinical condition 
in extremis.
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